Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
11.90
-0.15 (-1.24%)
At close: Dec 5, 2025, 4:00 PM EST
11.92
+0.02 (0.17%)
After-hours: Dec 5, 2025, 7:17 PM EST
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $231.10M in the quarter ending September 30, 2025, a decrease of -21.34%. This brings the company's revenue in the last twelve months to $788.90M, down -29.91% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$788.90M
Revenue Growth
-29.91%
P/S Ratio
0.81
Revenue / Employee
$876,556
Employees
900
Market Cap
624.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EBS News
- 18 days ago - Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - GlobeNewsWire
- 23 days ago - Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions: Solid Q3, Expecting Better Days To Come - Seeking Alpha
- 5 weeks ago - Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Emergent BioSolutions Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness - GlobeNewsWire
- 2 months ago - Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 - GlobeNewsWire
- 2 months ago - Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone - GlobeNewsWire